These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

667 related articles for article (PubMed ID: 32792503)

  • 1. Mex3a interacts with LAMA2 to promote lung adenocarcinoma metastasis via PI3K/AKT pathway.
    Liang J; Li H; Han J; Jiang J; Wang J; Li Y; Feng Z; Zhao R; Sun Z; Lv B; Tian H
    Cell Death Dis; 2020 Aug; 11(8):614. PubMed ID: 32792503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.
    Wei C; Dong X; Lu H; Tong F; Chen L; Zhang R; Dong J; Hu Y; Wu G; Dong X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):95. PubMed ID: 30791942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
    Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y
    Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGF2BP3 aggravates lung adenocarcinoma progression by modulation of PI3K/AKT signaling pathway.
    Chen X; Zhu X; Shen X; Liu Y; Fu W; Wang B
    Immunopharmacol Immunotoxicol; 2023 Jun; 45(3):370-377. PubMed ID: 36972188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEX3A promotes triple negative breast cancer proliferation and migration via the PI3K/AKT signaling pathway.
    Jiang S; Meng L; Chen X; Liu H; Zhang J; Chen F; Zheng J; Liu H; Wang F; Hu J; Li Z
    Exp Cell Res; 2020 Oct; 395(2):112191. PubMed ID: 32738346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agmatinase promotes the lung adenocarcinoma tumorigenesis by activating the NO-MAPKs-PI3K/Akt pathway.
    Zhu HE; Yin JY; Chen DX; He S; Chen H
    Cell Death Dis; 2019 Nov; 10(11):854. PubMed ID: 31699997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SMC2 knockdown inhibits malignant progression of lung adenocarcinoma by upregulating BTG2 expression.
    He Y; Wang Y; Luo Z; Zhang X; Bai H; Wang J
    Cell Signal; 2024 Aug; 120():111216. PubMed ID: 38729325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TM6SF1 suppresses the progression of lung adenocarcinoma and M2 macrophage polarization by inactivating the PI3K/AKT/mtor pathway.
    Huang S; Zhao H; Lou X; Chen D; Shi C; Ren Z
    Biochem Biophys Res Commun; 2024 Jul; 718():149983. PubMed ID: 38718735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GALNT2 promotes cell proliferation, migration, and invasion by activating the Notch/Hes1-PTEN-PI3K/Akt signaling pathway in lung adenocarcinoma.
    Wang W; Sun R; Zeng L; Chen Y; Zhang N; Cao S; Deng S; Meng X; Yang S
    Life Sci; 2021 Jul; 276():119439. PubMed ID: 33785338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The RNA binding protein MEX3A promotes tumor progression of breast cancer by post-transcriptional regulation of IGFBP4.
    Chen W; Hu L; Lu X; Wang X; Zhao C; Guo C; Li X; Ding Y; Zhao H; Tong D; Wang L; Huang C
    Breast Cancer Res Treat; 2023 Oct; 201(3):353-366. PubMed ID: 37433992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EIF4A3 Acts on the PI3K-AKT-ERK1/2-P70S6K Pathway through FLOT1 to Influence the Development of Lung Adenocarcinoma.
    Yu W; Liang J; Fang T; Jiang J; Zhao R; Li R; Han J; Tian H
    Mol Cancer Res; 2023 Jul; 21(7):713-725. PubMed ID: 37011005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of ARID1A expression promotes lung adenocarcinoma metastasis and predicts a poor prognosis.
    Sun D; Zhu Y; Zhao H; Bian T; Li T; Liu K; Feng L; Li H; Hou H
    Cell Oncol (Dordr); 2021 Oct; 44(5):1019-1034. PubMed ID: 34109546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SLC39A5 promotes lung adenocarcinoma cell proliferation by activating PI3K/AKT signaling.
    Liu Z; Hu Z; Cai X; Liu S
    Pathol Res Pract; 2021 Aug; 224():153541. PubMed ID: 34252710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer/testis antigen LDHC promotes proliferation and metastasis by activating the PI3K/Akt/GSK-3β-signaling pathway and the in lung adenocarcinoma.
    Chen L; Wu Q; Xu X; Yang C; You J; Chen F; Zeng Y
    Exp Cell Res; 2021 Jan; 398(2):112414. PubMed ID: 33301764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of FYN suppresses the epithelial-to-mesenchymal transition through down-regulating PI3K/AKT pathway in lung adenocarcinoma.
    Xue F; Jia Y; Zhao J
    Surg Oncol; 2020 Jun; 33():108-117. PubMed ID: 32561075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FAM83B promotes the invasion of primary lung adenocarcinoma via PI3K/AKT/NF-κB pathway.
    Zhang J; Wang J; Yue K; Li P; Shen W; Qiao X; Wang Y; Wu X
    BMC Pulm Med; 2023 Jan; 23(1):32. PubMed ID: 36690987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIAA1429 regulates lung adenocarcinoma proliferation and metastasis through the PI3K/AKT pathway by modulating ARHGAP30 expression.
    Guo W; Wang T; Huai Q; Guo L; Wang X; He J
    Thorac Cancer; 2024 Jun; 15(18):1397-1409. PubMed ID: 38717936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-212-5p exerts tumor promoter function by regulating the Id3/PI3K/Akt axis in lung adenocarcinoma cells.
    Chen FF; Sun N; Wang Y; Xi HY; Yang Y; Yu BZ; Li XJ
    J Cell Physiol; 2020 Oct; 235(10):7273-7282. PubMed ID: 32039486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ferredoxin 1: a gatekeeper in halting lung adenocarcinoma progression through activation of the GPRIN2 signaling pathway.
    Liu M; Wu S; Wu H; Zhou Y; Zhang X; Zhu D; Jiang J
    J Transl Med; 2024 May; 22(1):510. PubMed ID: 38802900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Junctional adhesion molecule-like protein as a novel target for kaempferol to ameliorate lung adenocarcinoma.
    Wu Q; Wang YB; Che XW; Wang H; Wang W
    J Integr Med; 2023 May; 21(3):268-276. PubMed ID: 37069006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.